bpc-157 safety adverse effects human data as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 – No Proof Required!
Description
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12
Immunity 50 , 12621275.e4 (2019)
Here are the key findings from several significant studies: 1
doi: 10.1093/jn/nxac143
